Marker Therapeutics (MRKR) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to -$19.0 million.
- Marker Therapeutics' Enterprise Value fell 11100.76% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.0 million, marking a year-over-year decrease of 11100.76%. This contributed to the annual value of -$19.2 million for FY2024, which is 2705.6% down from last year.
- Per Marker Therapeutics' latest filing, its Enterprise Value stood at -$19.0 million for Q3 2025, which was down 11100.76% from -$11.9 million recorded in Q2 2025.
- Over the past 5 years, Marker Therapeutics' Enterprise Value peaked at -$6.4 million during Q1 2023, and registered a low of -$64.5 million during Q1 2021.
- Moreover, its 5-year median value for Enterprise Value was -$18.1 million (2022), whereas its average is -$23.6 million.
- In the last 5 years, Marker Therapeutics' Enterprise Value soared by 7778.82% in 2023 and then plummeted by 11100.76% in 2025.
- Over the past 5 years, Marker Therapeutics' Enterprise Value (Quarter) stood at -$43.5 million in 2021, then skyrocketed by 72.91% to -$11.8 million in 2022, then dropped by 28.26% to -$15.1 million in 2023, then dropped by 27.06% to -$19.2 million in 2024, then grew by 1.09% to -$19.0 million in 2025.
- Its Enterprise Value was -$19.0 million in Q3 2025, compared to -$11.9 million in Q2 2025 and -$13.7 million in Q1 2025.